NanoKTN facilitates cancer drug partnership
BNC and London University School of Pharmacy sign service level agreement
The Nanotechnology Knowledge Transfer Network (NanoKTN), a UK network for micro and nanotechnologies, has facilitated a service level agreement (SLA) between two of its members.
The SLA between Bio Nano Consulting (BNC) and The School of Pharmacy, University of London will enable BNC to provide its clients with access to academic experts in pharmaceutics, pharmacology and drug discovery.
The partnership has already enabled BNC to secure a contract with an undisclosed US biotechnology company.
Under the terms of the contract, BNC will manage a project with scientists at The School of Pharmacy to formulate a phase I cancer drug with the goal of making the treatment orally available, rather than delivered intravenously. Once proof of concept is achieved, The School of Pharmacy will work with the company to take it to late-stage development.
Dr David Sarphie, ceo of BNC, said: ‘The SLA significantly expands our pool of scientists that we manage and draw upon for specific life science projects, including cancer research. Indeed, the pace with which we have already secured the first contract to apply the IP on offer at The School of Pharmacy, is testament to the standing in which The School of Pharmacy is held and the strength of the formulation technology that has been developed.’
Dr Sarphie added: ‘The NanoKTN plays an invaluable role in facilitating interaction between academia and industry. We look forward to continuing to support the excellent work of the NanoKTN and utilising its expertise in future collaborative ventures.’
